ArticleJournal of Taibah University Medical Sciences2026
Effects of mesenchymal stem cell secretome on osteoclast- and osteogenesis-related markers during orthodontic relapse.
Article in Journal of Taibah University Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The mesenchymal stem cell (MSC) secretome has emerged as a promising cell-free approach for modulating bone remodeling, but its effects during the orthodontic relapse phase remain poorly understood. This study investigated the effects of the human umbilical cord-derived MSC (hUC-MSC) secretome on alveolar bone remodeling during orthodontic relapse. Methods: Forty-one male Wistar rats were randomly assigned to three groups: negative control (C-), positive control (C+), and secretome-treated relapse group (S). S rats were subjected to submucosal injections of the hUC-MSC secretome, whereas the control groups received submucosal injection of phosphate-buffered saline. Orthodontic force was applied for 14 days to move the maxillary first molars mesially. Relapse began on day 14 after the appliance was removed. A retention device was placed only in C- rats. The rats were sacrificed on days 21 and 28, and the expression levels were assessed for cathepsin K (CTSK), tartrate-resistant acid phosphatase (TRAP), osteoprotegerin, receptor activator of nuclear factor-κB ligand, alkaline phosphatase (ALP), and osteocalcin (OCN) via immunohistochemistry. Results: Quantitative analysis demonstrated that the TRAP and CTSK expression levels were significantly lower in S than C-, but remained comparable to those in C+. In addition, the RANKL/OPG ratio was consistently lowest in S at both time points compared with C- and C+. Furthermore, across both observation periods, the expression levels of ALP and OCN were significantly higher in S compared with C-. Conclusion: The hUC-MSC secretome may promote a favorable alveolar bone remodeling balance at the tension side during orthodontic relapse by suppressing osteoclastic activity and enhancing osteoblastic activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.